biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech trial registry — 17 ClinicalTrials.gov studies with program phase, status, and indication context.
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
IO Biotech clinical trials
Registry index of 17 ClinicalTrials.gov studies linked to IO Biotech programs — each row shows trial ID, program name, phase, status, and indication.
IO Biotech trial registry — 17 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for IO Biotech.
-
SC201 (VICTORIA-01) — Phase 1
Clinical update -
IOB-022/KN-D38 — Phase 2
Clinical update -
IOB-013/KN-D18 — Phase 3
Clinical update -
IO102-IO103 in combination with pembrolizumab — Phase 2
Clinical update -
NRX 194204 — Phase 2
Clinical update -
IO102-IO103 — Phase 2
Clinical update -
PD-L1/IDO Peptide Vaccine — Phase 1
Clinical update -
IRX4204 — Phase 1
Clinical update
Trial registry
-
CTIS ↗ - 2024-511561-10-00CTIS ↗
IOB-022/KN-D38
Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗